CytoCore Announces Successful Early Testing for Bladder Cancer.

P2X7 Biomarker Highly Sensitive in Identification of Cancerous and Precancerous Tissue

CHICAGO -- CytoCore, Inc. (OTCBB:CYCR), a late-stage bio-scientific research company, today announced highly accurate results in using the P2X7 biomarker to detect bladder cancer -- suggesting much broader implications for its use in the early detection of cancer in all epithelial cells.

Following closely recent test results confirming the efficacy of the P2X7 marker in early identification of endometrial and cervical cancers, this new finding strongly indicates the biomarker's potential effectiveness in early screening for bladder cancer, in confirming the presence of bladder cancer in diagnostically difficult cases and perhaps in predicting the biologic potential of an individual tumor in terms of recurrence and progression to more advanced disease.

"One of the challenges in the field is to predict the malignant potential of an individual bladder neoplasm, since the pathologist's estimate of this parameter, in conjunction with other clinical criteria, strongly influences patient management," said Dr. Greg MacLennan, associate professor of pathology and director of the Tissue Procurement and Histology Core Facility at the Case Comprehensive Cancer Center, CASE (Case Western Reserve) University. "If the utility of P2X7 in bladder lesions is as good as in endometrial lesions, it has tremendous potential for use in the fields of urology and oncology."

Dr. MacLennan, who is collaborating with CytoCore, further added, "We are currently investigating whether the P2X7 biomarker can also differentiate borderline and precancerous lesions of the bladder, as was found to be the case in our studies of borderline and precancerous lesions of the uterine cervix and endometrium."

Dr. George Gorodeski, director of CytoCore's Scientific Advisory Board, explained that the P2X7 protein and mRNA had shown the ability to differentiate normal and cancer tissues both in uterine and urinary samples. "The reason could be that epithelia of the reproductive and urinary tracts arise from common embryonic sites and therefore may share common biological behavior and susceptibilities for the development of cancer. Statistical evaluation of the data revealed sensitivity and specificity rates of greater than 96 percent," stated Dr. Gorodeski.

These results confirm similar data, published recently in the American Association Cancer Research journal "Cancer Epidemiology Biomarkers & Prevention," that found the P2X7 biomarker highly effective in identifying endometrial and cervical cancers in women (see link at: http://cebp.aacrjournals.org/cgi/content/abstract/15/10/1906).

"Our findings, based on surgical tissue specimens taken from bladder cancer patients, are supported by the biology of the P2X7 marker, which is an apoptotic factor and suggests a causative relationship with cancer development," Dr. Gorodeski said. "We are further involved with validating these results and we plan to test an assay for early bladder detection in upcoming clinical trials."

CytoCore is currently in clinical trials and development with a range of screening, diagnostic and treatment products related to the P2X7 marker and its efficacy in the identification of pervasive reproductive cancers.

For further information, visit www.CytoCoreInc.com

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Dr. George Gorodeski has a significant financial interest in this research consisting of equity and salary as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.